Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: a mixed studies systematic review

We undertook this systematic review to determine the efficacy and safety of cannabis-based medicine as a treatment for behavioral, psychological, and motor symptoms associated with neurocognitive disorders

cAMP Signaling–Mediated Phosphorylation of Diacylglycerol Lipase α Regulates Interaction With Ankyrin-G and Dendritic Spine Morphology

Diacylglycerol lipase α (DAGLα), a major biosynthetic enzyme for endogenous cannabinoid signaling, has emerged as a risk gene in multiple psychiatric disorders. However, its role in the regulation of dendritic spine plasticity is unclear.

Cannabis and Psychosis: a Critical Overview of the Relationship

Authors: Charles Ksir, Carl L Hart Published in Current Psychiatry Reports February 2016 Abstract Interest in the relationship between cannabis use and psychosis has increased dramatically in recent years, in part…

Targeting the Endocannabinoid System in Psychiatric Illness.

Prevalence of psychiatric disorders continues to rise globally, yet remission rates and patient outcome remain less than ideal. As a result, novel treatment approaches for these disorders are necessary to decrease societal economic burden, as well as increase individual functi…

Survey of Psychiatrists On Medical Cannabis

Psychiatric Times invited psychiatrists to complete a survey about medicinal marijuana and didn’t expect nearly 2200 people to complete that survey in just a few days. The results, reported in…